Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human IGF-II Protein, 1mg  

Recombinant Human IGF-II Protein, 1mg

Recombinant Human IGF-II Protein, With N-Fc Tag (rhIGFII-Fc) Ala 25 - Glu 91 was produced in human 293 cells (HEK293)

Synonyms: TNFRSF9, 4-1BB, CD137, CDw137, ILA, Somatomedin-A, Insulin-like growth factor 2 (IGF-2), IGF protein hormone that share structural similarity to insulin

More details

IG2-H4260-1K

Availability: within 7 days

1 280,00 €

Background: Insulin-like growth factor 2 (IGF-2) also known as Somatomedin-A, IGF-II, PP9974, and is one of three protein hormones that share structural similarity to insulin. IGF-2 exerts its effects by binding to the IGF-1 receptor. IGF2 may also bind to the IGF-2 receptor (also called the cation-independent mannose 6-phosphate receptor), which acts as a signalling antagonist; that is, to prevent IGF2 responses. The major role of IGF2 is as a growth promoting hormone during gestation. In the process of Folliculogenesis, IGF2 is created by Theca cells to act in an autocrine manner on the theca cells themselves, and in a paracrine manner on Granulosa cells in the ovary. IGF2 promotes granulosa cell proliferation during the follicular phase of the menstrual cycle, acting alongside Follicle Stimulating Hormone (FSH). After ovulation has occurred, IGF-2 promotes progesterone secretion during the luteal phase of the menstrual cycle together with Luteinizing Hormone (LH). Thus, IGF2 acts as a Co-hormone together with both FSH and LH. IGF-2 may play a key role in memory and could potentially be used to treat Alzheimer\'s Disease. It is sometimes produced in excess in islet cell tumours, causing hypoglycemia. Doege-Potter syndrome is a paraneoplastic syndrome in which hypoglycemia is associated with the presence of one or more non-islet fibrous tumors in the pleural cavity. has been shown to interact with IGFBP3 and Transferrin.

Source
Recombinant Human IGF-II Protein, With N-Fc Tag (rhIGFII-Fc) Ala 25 - Glu 91 (Accession # P01344-1) was produced in human 293 cells (HEK293).

Molecular Characterization
rhIGFII-Fc, fused with Fc fragment of human IgG1 at the N-terminus, has a calculated MW of 35 kDa. DTT-reduced Protein migrates as 36 kDa.

Endotoxin
Less than 1.0 EU per μg of the rhIGFII-Fc by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM tris, 100 mM glycine, pH7.0. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
Immobilized Human IGFBP-3, His Tag (Cat. No. IG3-H5229) at 0.5 μg/mL (100 μL/well) can bind Human IGF-II, Fc Tag (Cat. No. IG2-H4260) with a linear range of 1-20 ng/mL (QC tested).

References


(1) MacRae, Fiona , 2011, Daily Mail (London).
(2) Balduyck B,et al., 2006, J Thorac Oncol 1 (6): 588–90.
(3) Storch, S, et al., 2001, FEBS Lett. (Netherlands) 509 (3): 395–8.
(4) Buckway, C K, et al., 2001, J. Clin. Endocrinol. Metab. (United States) 86 (10): 4943–50.
(5) Twigg, S M, Baxter R C, 1998, J. Biol. Chem. (UNITED STATES) 273 (11): 6074–9.
(6) Firth, S M; Ganeshprasad U, Baxter R C, 1998, J. Biol. Chem. (UNITED STATES) 273 (5): 2631–8.